Skip to main content
SpringerLink
Log in

Das multiple Myelom

Diagnose und Therapie

  • CME Fortbildung
  • Published:
CME Aims and scope

Zusammenfassung

Das multiple Myelom ist ein reifzelliges B-Zelllymphom mit einem Erkrankungsgipfel im höheren Lebensalter. Maligne Plasmazellen infiltrieren das Knochenmark und bestimmen über Interaktionen mit anderen Körperzellen und Organsystemen die individuell unterschiedliche klinische Symptomatik. Vorstadien sind die monoklonale Gammopathie unbestimmter Signifikanz und das Smoldering multiple Myelom, die üblicherweise keiner Behandlung bedürfen. Zur Diagnosesicherung eines therapiebedürftigen multiplen Myeloms sind verschiedene Laboruntersuchungen und bildgebende Verfahren nötig. Das Myelomprotein und die freien Leichtketten im Serum sind zur Verlaufsbeurteilung wichtige Surrogatmarker für die Tumormasse. Therapeutisch stehen konventionelle Chemotherapie, Proteasomeninhibitoren, Immunmodulatoren, monoklonale Antikörper, Hochdosischemotherapie, allogene Blutstammzelltransplantation, Strahlentherapie und verschiedene supportive Maßnahmen zur Verfügung. Die Therapie ist heute noch palliativ, Langzeitremissionen werden bei einzelnen Patienten beobachtet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Alexander, D.D., et al., Multiple myeloma: a review of the epidemiologic literature. Int.J.Cancer, 2007. 120 Suppl 12: p. 40–61.

    Article  PubMed  Google Scholar 

  2. Costa, L.J., et al., Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances, 2017. 1(4): p. 282–287.

    Article  Google Scholar 

  3. Kyle, R.A., et al., Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer, 2004. 101(11): p. 2667–2674.

    Article  PubMed  Google Scholar 

  4. Kyle, R.A. and S.V. Rajkumar, Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol., 2007. 139(5): p. 730–743.

    Article  CAS  PubMed  Google Scholar 

  5. Pont, S.R.d., et al., Genomics of Multiple Myeloma. Journal of Clinical Oncology, 2017. 35(9): p. 963–967.

    Article  Google Scholar 

  6. Morgan, G.J. and M.F. Kaiser, How to use new biology to guide therapy in multiple myeloma. ASH Education Program Book, 2012. 2012(1): p. 342–349.

    Google Scholar 

  7. Alexandrov, L.B., et al., Signatures of mutational processes in human cancer. Nature, 2013. 500(7463): p. 415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chapman, M.A., et al., Initial genome sequencing and analysis of multiple myeloma. Nature, 2011. 471(7339): p. 467–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Salmon, S.E. and B.A. Smith, Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest, 1970. 49: p. 1114–1121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dispenzieri, A., et al., Appraisal of immunoglobulin free light chain as a marker of response. Blood, 2008. 111(10): p. 4908–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kortüm, M., et al., Leitlinie: Monoklonale Gammopathie unklarer Signifikanz (MGUS), in onkopedia leitlinien, DGHO. e.V., Editor. 2010. https://www.onkopedia.com/de/onkopedia/guidelines/monoklonale-gammopathie-unklarer-signifikanz-mgus Zugegriffen: 16.6.2017

    Google Scholar 

  12. Kortüm, M., et al., Leitlinie: Multiples Myelom, in onkopedia leitlinien, DGHO. e.V., Editor. 2013. https://www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom Zugegriffen: 16.6.2017

    Google Scholar 

  13. Cretti, F. and G. Perugini, Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM). Radiol Med, 2016. 121(2): p. 93–105.

    Article  PubMed  Google Scholar 

  14. Princewill, K., et al., Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest, 2013. 31(3): p. 206–11.

    Article  PubMed  Google Scholar 

  15. Cavo, M., et al., Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol, 2017. 18(4): p. e206–e217.

    Article  PubMed  Google Scholar 

  16. Group, I.M.W., Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br.J.Haematol., 2003. 121: p. 749–757.

    Article  Google Scholar 

  17. Rajkumar, S.V., et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 2014. 15(12): p. e538–48.

    Article  PubMed  Google Scholar 

  18. Mateos, M.-V., et al., Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 2013. 369(5): p. 438–447.

    Article  CAS  PubMed  Google Scholar 

  19. Durie, B.G.M. and S.E. Salmon, A clinical staging system for multiple myeloma. Cancer, 1975. 36: p. 842–854.

    Article  CAS  PubMed  Google Scholar 

  20. Peest, D., et al., A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer, 1995. 31A: p. 146–151.

    Article  CAS  PubMed  Google Scholar 

  21. Palumbo, A., et al., Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015. 33(26): p. 2863–2869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Durie, B.G., et al., International uniform response criteria for multiple myeloma. Leukemia, 2006. 20: p. 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  23. Gerth, H.U., et al., Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS One, 2016. 11(5): p. e0154993.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Group, M.T.C., Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J.Clin.Oncol., 1998. 16: p. 3832–3842.

    Article  Google Scholar 

  25. Facon, T., et al., Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 2007. 370: p. 1209–1218.

    Article  CAS  PubMed  Google Scholar 

  26. San Miguel, J.F., et al., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 2008. 359(9): p. 906–917.

    Article  CAS  PubMed  Google Scholar 

  27. Sobh, M., et al., Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia, 2016. 30(10): p. 2047–2054.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland

    Dietrich Peest

Authors
  1. Dietrich Peest
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dietrich Peest.

Additional information

Interessenkonflikt

Der Autor gibt an, dass kein Interessenkonflikt besteht. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peest, D. Das multiple Myelom. CME 14, 51–63 (2017). https://doi.org/10.1007/s11298-017-5992-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11298-017-5992-3

Schlüsselwörter

Search

Navigation